心脏移植后1个月淋巴细胞减少与感染结局或死亡的相关性
单中心回顾性队列研究纳入2000至2018年375例成人心脏移植受者,评估移植后1个月绝对淋巴细胞计数(ALC)≤0.75×10^3 cells/µL与感染或死亡复合结局的关系。
要点
- 移植后1个月ALC≤0.75×10^3 cells/µL与感染或死亡风险升高相关。
- 该指标简单易得,或可作为心脏移植后感染风险的临床监测工具。
- 研究为单中心回顾性设计,结论需外部队列验证。
核心结论
- 心脏移植后1个月ALC≤0.75×10^3 cells/µL与随后11个月内感染结局或死亡风险升高独立相关。
研究设计与样本
- 单中心回顾性队列研究,分析2000至2018年成人心脏移植受者共375例。
主要发现
- 375例中101例(27%)发生复合结局,包括61例CMV、3例HSV/VZV、19例BSI、10例IFI和8例死亡。
关键数值与推荐
- 暴露定义为移植后1个月ALC≤0.75×10^3 cells/µL。
- 主要终点为移植后1个月至1年内发生的感染(CMV、HSV/VZV、BSI、IFI)或死亡的复合结局。
临床怎么用
- 心脏移植后1个月可检测ALC,若≤0.75×10^3 cells/µL提示后续感染或死亡风险升高,可考虑加强监测。
局限性
- 单中心回顾性队列研究,结果可能受中心实践和未测量混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cell-mediated immunity is a specific target of several medications used to prevent or treat rejection in orthotopic heart transplantation. Low absolute lymphocyte count (ALC) has potential to be a useful and accessible clinical indicator of overall infection risk. Though some studies have demonstrated this association in other transplant populations, it has not been assessed in heart transplant recipients. METHODS: A single-center retrospective cohort study examined adult heart transplant recipients transplanted between 2000 and 2018. The exposure of interest was ALC ≤0.75 × 103 cells/µL at 1 month posttransplant, and the primary endpoint was a composite outcome of infection (including cytomegalovirus [CMV], herpes simplex I/II or varicella zoster virus [HSV/VZV], bloodstream infection [BSI], invasive fungal infection [IFI]) or death occurring after 1 month and before 1 year posttransplant. A multivariable Cox proportional hazards model was created to control for confounders identified using clinical judgment and statistical criteria. RESULTS: Of 375 subjects analyzed, 101 (27%) developed the composite outcome (61 CMV, 3 HSV/VZV, 19 BSI, 10 IFI, 8 deaths). Lymphopenia (ALC ≤0.75 × 103 cells/µL) at 1 month was associated with a >2-fold higher rate of the composite outcome (hazard ratio [HR], 2.26 [95% confidence interval {CI}, 1.47-3.46]; P < .001) compared to patients without lymphopenia at 1 month. After adjustment for confounding variables, the presence of lymphopenia remained statistically significantly associated with the composite outcome (HR, 1.72 [95% CI, 1.08-2.75]; P = .02). CONCLUSIONS: ALC measured at 1 month after heart transplant is associated with an increased risk of infectious outcomes or death in the ensuing 11 months. This is a simple, accessible laboratory measure.
引用
- Perry WA, Paulus JK, Price LL, et al. Association Between Lymphopenia at 1 Month Posttransplant and Infectious Outcomes or Death in Heart Transplant Recipients. Clin Infect Dis. 2021. PMID: 33279963. doi:10.1093/cid/ciaa1800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。